The biopharmaceutical industry has experienced incredible exponential growth in recent decades. Annual revenues have increased from US$4.4 billion (£3.4 billion) in 1990 to $275 billion (£213 billion) in 2018 (a 6,250% increase) and now represent more than 25% of the total pharmaceutical market.1 A primary driver of this rapid expansion is the pioneering pursuit [...]
Crystal Lake, Illinois and Orlando, Florida (October 5, 2020) — Noble and Aptar Pharma are pleased to announce the launch of AdhereIT™ — a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT™ is the first fully [...]
With more biologics and drug delivery device options entering the market in recent years, pharma companies can decide whether it would be easier for patients to self-inject with an autoinjector or prefilled syringe, depending on drug viscosity and other factors. Some biologics also offer patients and their healthcare providers (HCPs) the ability to choose [...]
Nasal drug repurposing has seen a real resurgence recently, driven by several factors. From an economic perspective, partners benefit from reduced development costs, intellectual property (IP) creation, increased market share and extended lifecycle. The regulatory pathways, such as the US 505(b)2, sometimes complemented by orphan drug designation, are faster and less complex. It may [...]
Diagnoses of chronic illnesses such as rheumatoid arthritis (RA), Crohn’s disease and osteoporosis are expected to skyrocket in the coming decade, resulting in growing use of patient-centric drug delivery devices – including autoinjectors, prefilled syringes with safety features, and on-body and respiratory devices. Because of the complexity of injectable treatment regimens, onboarding aids – [...]
In the January 2020 edition of STAT News was a news release from 215 biopharma CEOs and industry leaders. The news release leverages 2020 as the beginning of “the dawn of a golden age of medicine [which] will soon have the ability to treat and cure diseases that have long been untreatable and incurable.” [...]
A primary goal of rheumatologists remains alleviating the pain, stiffness and tenderness that mark rheumatoid arthritis (RA). Yet in an era marked by a significant increase in self-injection options, it has become crucial for these HCPs to understand just how well their rheumatology patients are self-administering their medications. Currently, most RA patients undergo a [...]
Millions of patients worldwide living with rare, debilitating conditions are benefiting from developments in biopharmaceuticals and complex chemical entities as well as novel approaches to drug delivery. For example, many therapeutics administered in a subcutaneous injection are suitable for at-home administration by patients themselves, rather than in a healthcare facility. This includes wearable injection [...]
Chronic illnesses are on the rise, which means there are more and more patients who need to self-inject treatments at home. The problem is that patients who lack confidence in using their drug-delivery device or are inadequately familiar with the device tend to use it incorrectly and may not be receiving the full dose [...]